Last reviewed · How we verify

Calcipotriol Betamethasone ointment

Xijing Hospital · FDA-approved active Small molecule Quality 5/100

Calcipotriol Betamethasone ointment is a Small molecule drug developed by Xijing Hospital. It is currently FDA-approved.

At a glance

Generic nameCalcipotriol Betamethasone ointment
SponsorXijing Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Calcipotriol Betamethasone ointment

What is Calcipotriol Betamethasone ointment?

Calcipotriol Betamethasone ointment is a Small molecule drug developed by Xijing Hospital.

Who makes Calcipotriol Betamethasone ointment?

Calcipotriol Betamethasone ointment is developed and marketed by Xijing Hospital (see full Xijing Hospital pipeline at /company/xijing-hospital).

What development phase is Calcipotriol Betamethasone ointment in?

Calcipotriol Betamethasone ointment is FDA-approved (marketed).

Related